SCHEMBL2127763

SCHEMBL2127763

COC(=O)C1CC(F)(F)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
PTPN1 P18031 1/20 0.38
HSD17B10 Q99714 1/20 0.38
IMPDH2 P12268 3/20 0.37
EPHX2 P34913 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPC1 O15118 1/20 0.36
CCR2 P41597 4/20 0.36
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35
PEPD P12955 1/20 0.34
HSD11B1 P28845 1/20 0.34
IDH1 O75874 1/20 0.34
SCN4A P35499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30272143 1.00 NR1H2 (0.41) NR1H2NR1H3PTPN1HSD17B10IMPDH2
SCHEMBL10269862 1.00 NR1H2 (0.41) NR1H2NR1H3PTPN1HSD17B10IMPDH2
SCHEMBL15114477 0.87 POLB (0.38) EPHX2POLBPEPD
SCHEMBL10215476 0.86 HSD17B10 (0.45) NR1H2NR1H3HSD17B10EPHX2SMN1; SMN2
SCHEMBL1701540 0.86 PTPN1 (0.40) NR1H2NR1H3PTPN1HSD17B10IMPDH2
SCHEMBL10215488 0.86 HSD17B10 (0.39) HSD17B10EPHX2SMN1; SMN2NPC1CCR2
SCHEMBL706243 0.86 PTPN1 (0.40) NR1H2NR1H3PTPN1HSD17B10IMPDH2
SCHEMBL2126924 0.86 HSD17B10 (0.45) NR1H2NR1H3HSD17B10EPHX2SMN1; SMN2
SCHEMBL31148270 0.86 HSD17B10 (0.45) NR1H2NR1H3HSD17B10EPHX2SMN1; SMN2
SCHEMBL2207075 0.86 PTPN1 (0.40) NR1H2NR1H3PTPN1HSD17B10IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3427738-B1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMA (US) 2021-12-01 EP disclosed
EP-3427738-B1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMA (US) 2021-12-01 EP disclosed
CN-106928127-B Substituted piperidine amide derivative, preparation method and pharmaceutical application thereof 四川海思科制药有限公司 2021-07-16 CN disclosed
US-10874673-B2 Inhibitors of influenza viruses replication VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-12-29 US disclosed
US-10874673-B2 Inhibitors of influenza viruses replication VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-12-29 US disclosed
CN-104922128-B Inhibitors of influenza virus replication 沃泰克斯药物股份有限公司 2019-12-20 CN disclosed
CN-110540538-A Inhibitors of influenza virus replication VERTEX PHARMA 2019-12-06 CN disclosed
US-20190151314-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED 2019-05-23 US disclosed
US-20190151314-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED 2019-05-23 US disclosed
EP-3427738-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION Vertex Pharmaceuticals Incorporated (US) 2019-01-16 EP disclosed
US-20140142119-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-22 US disclosed
US-20140142119-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-22 US disclosed
US-20140142119-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-22 US disclosed
WO-2013106520-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 WO disclosed
US-20130183269-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 US disclosed
US-20120171245-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-05 US disclosed
US-20120171245-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-05 US disclosed
US-20120171245-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-05 US disclosed
EP-2442809-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION Vertex Pharmaceuticals Incorporated (US) 2012-04-25 EP disclosed
WO-2010148197-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151314-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION ACE, IRF3, ACE2 NR1H2 3111/4885NR1H3 3059/4885PTPN1 2522/4885
US-20130183269-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, EIF2AK2 NR1H2 2713/4885NR1H3 2533/4885PTPN1 344/4885
US-10874673-B2 Inhibitors of influenza viruses replication ACE, IRF3, ACE2 NR1H2 3111/4885NR1H3 3059/4885PTPN1 2522/4885
US-20120171245-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION ACE, IRF3, ACE2 NR1H2 3111/4885NR1H3 3059/4885PTPN1 2522/4885
US-20140142119-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION ACE, IRF3, ACE2 NR1H2 3111/4885NR1H3 3059/4885PTPN1 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.